David Howat
Chief Executive Officer Mariposa Therapeutics
Seminars
Thursday 5th November 2026
Advancing Disease-Modifying Therapies in Epidermolysis Bullosa Simplex to Move Beyond Wound Management & Restore Structural Integrity
11:30 am
- Targeting the underlying keratin dysfunction driving Epidermolysis Bullosa Simplex, restoring functional intermediate filament integrity rather than managing downstream symptoms, to shift treatment approaches from palliation toward true disease modification
- Exploring small-molecule strategies designed to rescue skin resilience at the cellular level, preventing blistering and mechanical fragility across EBS subtypes, to improve longterm mobility, wound burden and quality of life
- Building translational and regulatory pathways for first-in-class structural rescue therapies in rare disease, aligning patient need, biomarker development and early clinical strategy, to accelerate meaningful innovation in underserved genetic conditions
